191 related articles for article (PubMed ID: 37607227)
41. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
Luke JJ; Barlesi F; Chung K; Tolcher AW; Kelly K; Hollebecque A; Le Tourneau C; Subbiah V; Tsai F; Kao S; Cassier PA; Khasraw M; Kindler HL; Fang H; Fan F; Allaire K; Patel M; Ye S; Chao DT; Henner WR; Hayflick JS; McDevitt MA; Fong L
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608377
[TBL] [Abstract][Full Text] [Related]
42. Harnessing the potential of CD40 agonism in cancer therapy.
Zhou Y; Richmond A; Yan C
Cytokine Growth Factor Rev; 2024 Feb; 75():40-56. PubMed ID: 38102001
[TBL] [Abstract][Full Text] [Related]
43. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
[TBL] [Abstract][Full Text] [Related]
44. Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy.
Jacoberger-Foissac C; Blake SJ; Liu J; McDonald E; Triscott H; Nakamura K; Smyth MJ; Teng MW
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199513
[TBL] [Abstract][Full Text] [Related]
45. The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.
Merz C; Sykora J; Marschall V; Richards DM; Heinonen K; Redondo Müller M; Thiemann M; Schnyder T; Fricke H; Hill O; Gieffers C
J Immunother; 2018; 41(9):385-398. PubMed ID: 30273198
[TBL] [Abstract][Full Text] [Related]
46. IL-15 in the Combination Immunotherapy of Cancer.
Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
Front Immunol; 2020; 11():868. PubMed ID: 32508818
[TBL] [Abstract][Full Text] [Related]
47. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.
Funakoshi S; Longo DL; Murphy WJ
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):93-101. PubMed ID: 8732692
[TBL] [Abstract][Full Text] [Related]
48. Agonistic CD40 Antibodies in Cancer Treatment.
Djureinovic D; Wang M; Kluger HM
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804039
[TBL] [Abstract][Full Text] [Related]
49. CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors.
Labiano S; Roh V; Godfroid C; Hiou-Feige A; Romero J; Sum E; Rapp M; Boivin G; Wyss T; Simon C; Bourhis J; Umaña P; Trumpfheller C; Tolstonog GV; Vozenin MC; Romero P
Clin Cancer Res; 2021 Jul; 27(14):4054-4065. PubMed ID: 33903200
[TBL] [Abstract][Full Text] [Related]
50. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
51. Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy.
Baumann D; Hägele T; Mochayedi J; Drebant J; Vent C; Blobner S; Noll JH; Nickel I; Schumacher C; Boos SL; Daniel AS; Wendler S; Volkmar M; Strobel O; Offringa R
Nat Commun; 2020 May; 11(1):2176. PubMed ID: 32358491
[TBL] [Abstract][Full Text] [Related]
52. Systemic immune response to a CD40 agonist antibody in nonhuman primates.
Caudell DL; Dugan GO; Babitzki G; Schubert C; Braendli-Baiocco A; Wasserman K; Acona G; Stern M; Passioukov A; Cline JM; Charo J
J Leukoc Biol; 2024 May; 115(6):1084-1093. PubMed ID: 38372596
[TBL] [Abstract][Full Text] [Related]
53. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH
J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585
[TBL] [Abstract][Full Text] [Related]
54. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
[TBL] [Abstract][Full Text] [Related]
55. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
[TBL] [Abstract][Full Text] [Related]
56. A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation.
Mega A; Mebrahtu A; Aniander G; Ryer E; Sköld A; Sandegren A; Backström Rydin E; Rockberg J; Östman A; Frejd FY
MAbs; 2023; 15(1):2223750. PubMed ID: 37332119
[TBL] [Abstract][Full Text] [Related]
57. Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.
Medina-Echeverz J; Ma C; Duffy AG; Eggert T; Hawk N; Kleiner DE; Korangy F; Greten TF
Cancer Immunol Res; 2015 May; 3(5):557-66. PubMed ID: 25637366
[TBL] [Abstract][Full Text] [Related]
58. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.
Jiang Q; Weiss JM; Back T; Chan T; Ortaldo JR; Guichard S; Wiltrout RH
Cancer Res; 2011 Jun; 71(12):4074-84. PubMed ID: 21540234
[TBL] [Abstract][Full Text] [Related]
59. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
60. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
